Replies to post #35233 on Relief Therapeutics Holding AG (RLFTF)

[Vanilla Fitbit]

IF THE INHALER IS SO IMPORTANT


WHICH WE ALL AGREE IT IS.... THEN THAT ONLY SUPPORTS THE FRUSTRATION AS
TO WHY RELIEF THERAPEUTICS, THE COMPANY WE ARE INVESTED IN, THE COMPANY THAT HOLDS THE PATENT, DID ABSOLUTELY ZERO PRESS RELEASE ON START OF THE INHALER TRIAL.

MAKES ZERO SENSE UNLESS THE IDEA PRESENTED OF COLLUSION BETWEEN RELIEF AND GEM TO SUPPRESS SHARE PRICE FOR THE 15 DAYS NEEDED TO FULLFILL TERMS OF SSF SO GEM GETS THE MOST POSSIBLE SHARES....

IF THEY DELAY WE WILL KNOW THIS IS WHY
IF WE FIND OUT THEY DREW DOWN ALL OR MOST OF SSF THATS MORE EVIDENCE...

All truths are easy to understand once they are discovered; the point is to discover them.
Galileo Galilei

[mc67]

$RLFTF #TheMath

GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ --

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) Relief Therapeutics and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil)
(Zyesami ) worldwide.

The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.

They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.

Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.

http://www.prnewswire.com/news-releases/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners-301134379.html